

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number
WO 2025/179128 A8

(43) International Publication Date
28 August 2025 (28.08.2025)

(51) International Patent Classification:

A61K 31/472 (2006.01) *A61P 25/22* (2006.01)
A61P 25/08 (2006.01) *A61P 25/24* (2006.01)

NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN,
WS, ZA, ZM, ZW.

(21) International Application Number:

PCT/US2025/016769

(22) International Filing Date:

21 February 2025 (21.02.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/556,681 22 February 2024 (22.02.2024) US

(71) Applicant: **XENON PHARMACEUTICALS INC.**
[CA/CA]; 3650 Gilmore Way, Burnaby, BC V5G 4W8
(CA).

Published:

— with international search report (Art. 21(3))

(48) Date of publication of this corrected version:

18 June 2026 (18.06.2026)

(15) Information about Correction:

see Notice of 18 June 2026 (18.06.2026)

(72) Inventors: **BEATCH, Gregory, N.**; C/o Xenon Pharma-
ceuticals Inc., 3650 Gilmore Way, Burnaby, BC V5G 4W8
(CA). **BUTTERFIELD, Noam, Douglas Nahum**; C/o
Xenon Pharmaceuticals Inc., 3650 Gilmore Way, Burnaby,
BC V5G 4W8 (CA). **DHAKAR, Monica, Bhagwansingh**;
C/o Xenon Pharmaceuticals Inc., 3650 Gilmore Way, Burn-
aby, BC V5G 4W8 (CA). **FORGACS, Peter, Bertalan**; C/
o Xenon Pharmaceuticals Inc., 3650 Gilmore Way, Burna-
by, BC V5G 4W8 (CA). **GRAYSON, Celene**; C/o Xenon
Pharmaceuticals Inc., 3650 Gilmore Way, Burnaby, BC
V5G 4W8 (CA). **NAMDARI, Rostam**; C/o Xenon Phar-
maceuticals Inc., 3650 Gilmore Way, Burnaby, BC V5G
4W8 (CA). **ODINECS, Aleksandrs**; C/o Xenon Pharma-
ceuticals Inc., 3650 Gilmore Way, Burnaby, BC V5G 4W8
(CA).

(74) Agent: **SAMBLANET, Danielle, C.** et al.; Wolf, Green-
field & Sacks, P.C., 600 Atlantic Avenue, Boston, MA
02210-2206 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,

(54) Title: AZETUKALNER FOR USE IN THE TREATMENT OF DEPRESSION, ANHEDONIA OR A SEIZURE DISORDER
SUCH AS EPILEPSY IN PEDIATRIC SUBJECTS

(57) Abstract: In certain embodiments, the present disclosure is directed to methods for treating disorders, including depressive dis-
orders, seizure disorders, and anhedonia, in a pediatric subject, wherein the methods comprise orally administering a therapeutically
effective amount of the voltage-gated potassium channel allosteric modulator, A-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-
dimethylphenyl]-3,3-dimethylbutanamide (azetukalner), or a pharmaceutically acceptable salt thereof, to the pediatric subject, for ex-
ample, under fed conditions.



WO 2025/179128 A8